Although the roles of MYB and MYB-NFIB in the formation of recurrent ACC after treatment are not completely understood, the observed activities of certain VEGFR-targeting kinase inhibitors are promising. The gene discussed is NFIB; the disease is adrenal cortex carcinoma.